Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651384 | 0.80 | TSHR (0.54) | CYP2C19CYP2D6CYP2C9RECQLTSHR | |
| SCHEMBL2342303 | 0.80 | PRSS1 (0.45) | MMP13TSHRALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL14923016 | 0.77 | CYP2D6 (0.52) | CYP2C19CYP2D6CYP2C9RECQLTSHR | |
| SCHEMBL496751 | 0.77 | TSHR (0.61) | CYP2C19CYP2D6CYP2C9MMP13TSHR | |
| SCHEMBL14060330 | 0.76 | TSHR (0.56) | CYP2C19CYP2D6CYP2C9TSHRMAOB | |
| SCHEMBL1016551 | 0.75 | TSHR (0.59) | CYP2C19CYP2D6CYP2C9TSHRMAOB | |
| Hydrochloric Acid SCHEMBL27821527 | 0.75 | TSHR (0.59) | CYP2C19CYP2D6CYP2C9MMP13TSHR | |
| SCHEMBL8870409 | 0.75 | TSHR (0.59) | CYP2C19CYP2D6CYP2C9MMP13TSHR | |
| SCHEMBL7131786 | 0.75 | TSHR (0.62) | CYP2C19CYP2D6CYP2C9TSHRALDH1A1 | |
| SCHEMBL26640739 | 0.75 | TSHR (0.48) | CYP2C19CYP2D6CYP2C9RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2359819-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | Temple University - Of The Commonwealth System of Higher Education (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1328511-B1 | SUBSTITUTED (E)-STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7053123-B2 | Substituted (e)-styryl benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1328511-A4 | SUBSTITUTED (E)-STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050101528-A1 | Substituted (e)-styryl benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2005-05-12 | — | — | US | disclosed |
| US-6642410-B2 | Useful as antiproliferative agents, including, for example, anticancer agents | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-11-04 | — | — | US | disclosed |
| EP-1328511-A1 | SUBSTITUTED (E)-STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1305015-A4 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1305015-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | REDDY E PREMKUMAR (US) | 2003-02-20 | — | — | US | disclosed |
| US-6486210-B2 | SUCH AS ENANTIOMORPHS OF 4-FLUOROSTYRYL-2,3,4,5,6-PENTAFLUOROBENZYLSULFONE; ANTIPROLIFERATIVE/ANTICANCER AGENTS | Temple University—Of the Commonwealth System of Higher Education | 2002-11-26 | — | — | US | disclosed |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-08-22 | — | — | US | disclosed |
| WO-2002028828-A1 | SUBSTITUTED (E)-STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001078712-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | MKI67, MCL1, CCNA1 | CYP2C19 4036/4885CYP2D6 3810/4885CYP2C9 4435/4885 |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | HCCS, CCNO, HRAS | CYP2C19 4680/4885CYP2D6 2646/4885CYP2C9 4750/4885 |
| US-20050101528-A1 | Substituted (e)-styryl benzylsulfones for treating proliferative disorders | CCNO, HCCS, CCNT1 | CYP2C19 4165/4885CYP2D6 2116/4885CYP2C9 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.